Next-generation sequencing
A DNA sequencing method that enables simultaneous sequencing of multiple DNA segments in a high-throughput manner. Also known as massively parallel sequencing.
Whole exome sequencing
Targeted capture and sequencing of the exome using next-generation sequencing. This method offers a powerful approach towards the identification of monogenic disease-causing genes.
Variant
A difference in a DNA sequence compared to a 'normal' reference sequence. A variant can be benign (for example, a single nucleotide polymorphism) or diseasecausing (for example, a mutation).
Allele
Specific DNA sequence variant in a given gene. Alleles can be designated according to their frequency as common or rare alleles.
Phenotype
The observable characteristics of an individual as a morphological, clinical or biochemical trait. A phenotype can also be the presence or absence of a disease.
Genotype
The set of alleles (variants of genes) that structure an individual's genetic makeup.
Expressivity
Variation of the expression of the phenotype among affected individuals with the same genotype. Variable expressivity refers to different degrees of severity and/or organ involvement in different affected individuals that carry an identical mutation.
in developed countries outside the USA 13 . Their aetiologies have only been revealed in the past decade, with the identification of single-gene (monogenic) mutations providing insights into the pathomechanisms of early-onset CKD. This improved understanding of disease pathogenesis is exemplified, for instance, by the discovery of mutations in NPHS1 (which encodes nephrin), as a cause of congenital nephrotic syndrome, thereby identifying podocyte dysfunction as central to the pathogenesis of this disease [14] [15] [16] . Monogenic diseases (also referred to as Mendelian or single-gene disorders) result from mutations in a single causative gene. Patterns of Mendelian inheritance can be autosomal dominant, autosomal recessive or X-linked. In the past 15 years >200 monogenic causes of earlyonset CKD have been identified (TABLE 1) . Most of these causative genes have been discovered in the past 5 years owing to an acceleration in gene discovery with the develop ment of modern genetic mapping and whole exome sequencing (WES) technologies. Approximately 36 genes are currently known to be mutated in CAKUT 5, 9, 10, 17 , 39 in SRNS 18, 19 , 10 in chronic glomerulonephritis, and >95 in renal cystic ciliopathies 3, 20 . These data demonstrate that a monogenic cause of disease can be identified by mutation analysis in ~20% of patients with early-onset CKD (TABLE 1) .
Attributing causality
The degree to which causality is attributed to a certain genetic variant can be classified according to the penetrance of a given disease-causing allele. The degree of genetic penetrance reflects the proportion of individuals with the genetic variant(s) who express the disease phenotype. At one end of the spectrum are autosomal recessive monogenic Mendelian diseases (also known as single-gene disorders), which are characterized by tight genotype-phenotype correlations such that the disease phenotype is almost entirely determined by mutations in a single gene -that is, they show 'full penetrance' (REF. 21 ; TABLE 2). For example, indivi duals who carry mutations in both copies of NPHP1 will develop juvenile nephron ophthisis 22 , progressing to CKD with renal fibrosis and cysts by the age of 20 years. By contrast, genotype-phenotype correlations can be weaker for auto somal dominant monogenic Mendelian diseases owing to multiple features of these diseases, such as increasing disease penetrance with increasing age; incomplete penetrance, such that some individuals with the mutation do not develop the disease phenotype and the disease can therefore seem to skip a generation in a pedigree; and variable expressivity of the disease such that different organs are affected with differing degrees of severity between individuals (TABLE 2 ). An example of an autosomal dominant kidney disease with variable expressivity is that caused by HNF1B mutations, which can cause CAKUT, CKD and maturity-onset diabetes of the young (MODY) with variable age of onset 23, 24 . Variable expressivity mainly describes a complex genotype-phenotype relationship in autosomal dominant diseases; however, a similarly complex situation can exist in recessive diseases that exhibit 'multiple allelism' -the finding that different (homo zygous) recessive mutations in the same gene can lead to different clinical outcomes. For instance, certain mutations in LAMB2 that cause nephrotic syndrome might lack ocular involvement in some individuals 25 , or specific combinations of compound heterozygous mutations of NPHP2 might cause adult-onset rather than childhood-onset nephrotic syndrome 26 .
At the other end of the spectrum of causality are more common conditions for which low-penetrance, so-called 'risk alleles' , have been described 21 . In these conditions, which often are referred to as polygenic or complex diseases, genetic variants usually exert only small effects on the disease (TABLE 2) and thus only a small fraction of the statistical variance for a disease phenotype can usually be assigned to a risk allele. An exception to this situation occurs with APOL1 variants, which convey a large phenotypic risk for the development of focal segmental glomerulosclerosis (FSGS) and CKD in African Americans [27] [28] [29] [30] [31] (TABLE 2) . For instance, an estimated 13-23% of African Americans (compared with 0.3-1.3% of European Americans) have one of the two known APOL1 risk alleles 32, 33 . The risk of developing FSGS is increased 17-fold for African Americans who carry two risk alleles compared with that of individuals who carry no risk alleles or one risk allele 32, 33 . Finally, the contribution of genetic modifiers to the disease phenotype is another aspect of genetic causality that should be taken into consideration. This concept, in which specific alleles are responsible for the modification of disease phenotypes, has been described for monogenic forms of cystic kidney disease 34 and glomerulonephritis 35 . Nonetheless, additional supporting evidence is needed for some of these associations in early-onset CKD.
We 10 as well as others 36 have noted that gene variants are often falsely assigned disease causality. Specifically, up to 30% of genetic variants that have been published as likely disease-causing and deposited in genetic databases have not been confirmed as deleterious 37 . Consequently, any attribution of pathogenicity to a given variant should be subject to strict criteria and multiple levels of evidence, such as amino acid sequence conservation, segregation analysis, tissue specific gene expression, functional studies, and animal models, should be considered 36, 38 . To decide whether a genetic variant qualifies as potentially disease-causing we follow empiric core rules
Key points
• Approximately 20% of cases of chronic kidney disease (CKD) that manifest before the age of 25 years are caused by single gene mutations in any one of >200 different genes • Molecular genetic diagnostics can provide patients with a molecular diagnosis for their disease and can generate new insights into disease mechanisms • Molecular genetic diagnostics might also have consequences for personalized treatment and prevention of CKD • Indication-driven mutation analysis panels are available to guide the genetic diagnosis of common early-onset kidney diseases, such as congenital anomalies of the kidneys and urinary tract, steroid-resistant nephrotic syndrome, ciliopathies and nephrolithiasis
Exon
The protein coding part of a gene. Exons are spliced together following gene transcription to form mRNA, which is translated into protein.
that have been described elsewhere 18 . These core rules are not absolute, and provide only general guidance. Furthermore, the number of families with early-onset CKD that have been previously reported to have a mutation in the candidate causative gene should also be considered. For instance, some CAKUT-causing genes have been reported only in single families and therefore any generalization regarding their role must await their description and characterization in additional patients.
Indication-driven gene panel analysis
Mutation analysis in recessive or dominant monogenic kidney diseases can reveal the primary cause of a disease that results from an inherited disease-causing gene. Such analyses can enable disease entities to be categorized on the basis of their genetic aetiologies. As monogenic causes of early-onset CKD (TABLE 1) can be found in a substantial portion of affected individuals 3, 10, [39] [40] [41] [42] [43] , we suggest that patients with early-onset CKD who are enrolled in clinical research or drug trials undergo molecular genetic diagnostics to enable cases of 'monogenic disease' to be accounted for in downstream epidemiologic analyses. Failure to do so might confound any conclusions from these studies. Moreover, molecular genetic diagnostics enables prenatal testing and might have prognostic or even therapeutic implications.
We have developed indication-driven diagnostic exon sequencing panels 42 for CAKUT 9, 10 , SRNS 44 , renal cystic ciliopathies 42 , glomerulonephritis, and nephrolithiasis or nephrocalcinosis 45 . These five diagnostic groups of CKD alone encompass 72.8% of CKD that manifests before the age of 25 years (TABLE 1) . Using a microfluidic technique to perform multiplex PCR-based amplification of 600 exons from ~30 different genes that are known to be mutated in the respective CKD diagnostic groups, we established a cost-effective mutation analysis screen for large patient cohorts. This method requires that DNA PCR products from each individual are barcoded before next-generation sequencing is performed [6] [7] [8] [9] [10] 41, 42 so that hundreds of PCR products can be sequenced in a single run, thereby drastically reducing costs. Indications to run a diagnostic panel are kept simple (TABLE 1) to ensure that future applications of the panels will achieve similar results. For instance, the indication to run the CAKUT panel is any imaging study showing evidence of CAKUT (such as renal aplasia, renal hypodysplasia, vesicoureteral reflux or uretero pelvic junction obstruction) 10 . For the proteinuria panel the indication is SRNS 8, 44 . For the nephrolithiasis (uri nary stone disease) panel the indication is any history of nephro lithiasis and/or nephrocalcinosis 45 . For the glomerulo nephritis panel the indication is the presence of proteinuria and haematuria. For the renal cystic ciliopathy panel the indication is the presence of two or more renal cysts or increased renal echogenicity on renal sonography 3, 42, 46 . Of note, over 95 known genes that molecularly explain the vast majority of cases of renal ciliopathies (~70%) have been described.
CAKUT panel
Using gene panels we examined a large international cohort of 650 unrelated families with CAKUT for the presence of mutations in 17 autosomal dominant and six autosomal recessive genes that are known to cause CAKUT 9,10 . Our results showed that >8% of cases of CAKUT are caused by single-gene mutations in one of 23 autosomal dominant or recessive genes. These data together with findings from two independent studies 47, 48 in which copy number variations were identified among 10-16% of individuals with CAKUT (most commonly involving the HNF1B or the DiGeorge/velocarodiofacial locus), suggest that monogenic genes might cause CAKUT in around 17% of cases (TABLES 1,3). 49, 50 . WT1 mutations in patients with SRNS can predispose to certain malignancies; consequently, the detection of WT1 mutations should trigger monitoring and further evaluation of affected individuals for associ ated tumours that include Wilms tumour and gonado blastoma. The latter entity has been mainly described in association with a concomitant abnormal chromosomal karyotype and therefore a karyotype analysis should also be obtained for patients with WT1 mutations 51 . Furthermore, identification of the causative mutation might reveal a therapeutic approach for some rare single-gene causes of SRNS. For example, experimental treatment with coenzyme Q 10 (CoQ 10 ) might be warranted for patients with mutations in genes that encode enzymes of CoQ 10 biosynthesis (COQ2, COQ6, ADCK4, or PDSS2) 52, 53 . Partial response to treatment with CoQ 10 Small Rho-like GTPases (RhoA/Rac1/Cdc42) are part of another pathway that has been implicated in the pathogenesis of nephrotic syndrome through the identification of mutations in the SRNS genes ARHGDIA, KANK1, KANK2, and KANK4, which are regulators of Rho-like GTPase, and through elucidation of the response of the calcineurin target synaptopodin to ciclosporin treatment in patients with SRNS [55] [56] [57] . Individuals with mutations in CUBN that cause vitamin B 12 deficiency might be amenable to treatment with vitamin B 12 , and individuals with ARHGDIA could theoretically be responsive to the mineralocorticoid-receptor blocker eplerenone through modulation of Rac I-mineralocorticoid interaction 55 . Finally, two children with recessive mutations in PLCE1 responded fully to treatment with steroids or ciclosporin 58 . Feasible Difficult
Proteinuria panel

Examples of genes mutated in kidney diseases
NPHP1, NPHS1 PAX2, HNF1B APOL1
GWAS, genome-wide association studies; NA, not applicable; WES, whole exome sequencing; WGS, whole genome sequencing. *Applicable to consanguineous families.
In the future it might be advisable to initiate mutation analysis of all known nephrosis genes in any patient with an episode of proteinuria persistent for >3 days (urine protein greater than 4 mg/m 2 per h). In a first episode with gross proteinuria steroid treatment might be commenced at the same time as mutation analysis is initiated. If results from the mutation analysis are returned within a few weeks, they might then guide the decision as to whether steroid treatment should be continued or terminated, depending on whether sufficient data exist to suggest that the presence of a certain mutation warrants discontinuation of treatment. Using this approach unnecessary steroid toxicity could be avoided.
Nephritis panel
In individuals with a diagnostic constellation compatible with chronic glomerulonephritis (that is, small grade proteinuria with microscopic haematuria), exon sequencing of 10 monogenic nephritis genes yields a monogenic cause of nephritis in ~20% of individuals 59 (TABLES 1,5).
Cystic kidney disease panel
In 50-70% of individuals who exhibit the presence of two or more cysts and/or a finding of increased echogenicity by ultrasonography, a monogenic cause of disease can be detected by exon sequencing of 95 genes 3, 41, 42, 46 (TABLES 1,6). PKD1 and PKD2, which are mutated in auto somal dominant kidney disease (ADPKD) are not part of this panel for several reasons. First, analysis of mutations in PKD1 and PKD2 requires a very specialized approach as it involves genotyping of long-range PCR fragments 60 ; second, the manifestation of disease in patients with ADPKD often occurs after 25 years-of-age; and third, mutation analysis is rarely requested within the polycystic kidney disease community as molecular diagnosis is valuable in only a few specific situations and mostly not in paediatric patients.
Nephrolithiasis panel
We have demonstrated that 21% of cases of nephrolithiasis and/or nephrocalcinosis with onset before the age of 18 years and 12% of cases with onset after the age of 18 years can be explained by mutations in one of 14 genes 45 (TABLES 1,7). The cystinuria gene SLC7A9 is the most frequently mutated in these individuals, with mutations identified in 15% of our study cohort 45 . Molecular diagnosis of urinary stone disease has important implications for affected individuals as well as for unaffected family members. Genetic screening of asymptomatic rela tives might identify individuals who carry the diseasecausing mutation; this information will guide clin icians to monitor these individuals for the development of disease and to institute preventive treatment when appropriate. In addition, standard treatment for urinary stone disease, such as increasing fluid intake, limiting sodium intake, use of thiazide diuretics and potassium citrate 61 , might not directly address the pathophysiology of particular molecular diagnoses. For example, clinicians should monitor for tetany and seizures, which have been reported in patients with CLDN16 mutations 62 . In summary, we expect that the use of diagnostic exon sequencing panels will expand the number of genes examined for each of these CKD groups in the future. In addition, other exon sequencing panels will be introduced into clinical practice to detect monogenic causes of CKD in additional diagnostic groups of early-onset CKD, 
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for example, in patients with monogenic forms of hypertension. The ongoing discovery of novel genes that cause CKD when mutated, together with the continuing trend of cost reduction in exome sequencing technol ogies, suggests that in the near future, indication-driven molecular genetic diagnostics will be performed using WES, which sequences the exons of all 20,000 genes in the human genome in parallel at low cost 3, 63 . However, in this context it will be important to maintain an indication-driven a priori approach, in which only genes known to cause the respective disorder are evaluated for mutations on the basis of clearly defined clinical indication criteria as described above (TABLE 1) .
Generalizability of mutation detection rates
Generalizations regarding the rates of mutations detected across the different aetiologies of early-onset CKD and among different populations should take several important factors into consideration. First are the effects of consanguinity and patient age on mutation rates across different disease cohorts. In our analyses of families with early-onset SRNS and urinary stone disease, the proportion of individuals in whom a molecular genetic diagnosis was made correlated inversely with age of disease onset and directly with degree of consanguinity 44, 45 . Although our findings suggest that different mutation rates might apply to cohorts with differing ages of disease onset or degrees of consanguinity, we think that our reported rates of mutation in SRNS will translate to other cohorts, as similar mutation rates have been confirmed by two independent European groups 19, 64 . Likewise, we have shown that causative mutations can be identified in approximately 18-21% of patients with childhoodonset urinary stone disease (F. Hildebrandt, unpublished work) 45 . Of course, the success rates of mutation identification will most likely increase as a greater number of monogenic renal genes and mutations are identified.
Second, as more data from extensive whole exome studies on human genetic variation accrue, questions regarding incomplete penetrance of certain alleles can be addressed and studied. A degree of incomplete penetrance and variable expressivity is increasingly apparent, especially for monogenic dominant causes of CAKUT but also for other recessive aetiologies. For instance, in early-onset SRNS for which recessive disease-causing mutations are fairly frequent and often convey full penetrance, a few exceptions in which mutated genes seem to convey partial penetrance have also been described 65 . Third, the potential for false positive attribution of mutated genes as being monogenic disease-causing as a result of inappropriate filtering criteria or increased sequencing of patients who might have a low probability of having monogenic disease can also hamper the true frequency of mutation detection rates. Minimizing the false assignment of genetic variants as disease-causing will be one of the most important tasks in the renal research area over the next 10 years. Confirmation of the disease-causing role of identified genes is required through use of cell-based functional assays, animal models, and large databases that describe genetic variants in large multinational populations. Fourth, for dominantly 
Exome
The protein coding sequences of the entire genome (comprising ~1% of the human genome).
Variant filtering
The process of excluding variants as disease-causing. For instance, very common variants and variants that do not alter the protein sequence are excluded.
Homozygosity mapping
A technique in which the homozygous regions across the genome are identified. This strategy is effective for the discovery of autosomal recessive monogenic disease genes in consanguineous families.
Phenocopies
A variation in a phenotype of given trait that can mimick a different trait.
inherited conditions, the presence of familial cases will often also positively influence the rate at which mutations are detected 66 . Finally, one additional concern of mutation analysis is the potential adverse effects of screening for monogenic disease-causing mutations in unaffected family members. The finding of a mutated candidate gene could be particularly detrimental to an individual if the disease allele is incompletely penetrant or shows variable expressivity, leading to prognostication of an unfavourable health condition that might never manifest. In this context it is important to observe the recommendation by the American College of Medical Genetics and Genomics 67 , which discourages mutation analysis in individuals who have not manifested with symptoms of disease. Nonetheless, certain circumstances exist in which clinical judgment should be applied in which a disease can be 'silent' or 'subtle' , whereby apparently 'unaffected' persons are in fact asymptomatic (for example, in patients with asymptomatic nephrocalcinosis or asymptomatic renal hypodysplasia).
Novel gene discoveries using WES
The exome comprises the entirety of all exon-encoding sequences in a genome. Although the exome represents only 1% of the human genome, it contains all of the protein-encoding sequences. Sequencing of the exome through WES therefore offers a powerful approach towards the identification of novel monogenic causes of disease. A detailed description of WES can be found elsewhere 68, 69 , but briefly, the technique involves the sequencing of short fragments of genomic DNA that have been hybridized to oligonucleotides representing exons of the human genome. The millions of sequencing reads that are generated are aligned for comparison with a 'normal' reference sequence of the human genome and a WES data output file is generated, which contains all genetic variants from the reference sequence that are found in the DNA of the tested individual. If a genetic sequence variant leads to a phenotypic change, for instance causes disease, that sequence variant is called a 'mutation' . Other sequence variants are called 'variances of unknown significance' .
The identification of mutations in novel diseasecausing genes using WES can reveal previously unrecognized causes of disease. For instance, WES analyses first revealed a role for mutations in genes that are involved in CoQ 10 biosynthesis -COQ2, COQ6, ADCK4 and PDSS2 -in the pathogenesis of SRNS [52] [53] [54] . However, the utility of WES for novel gene discovery is hampered by the fact that a large number of genetic variants are identified by comparing the exome sequences of an individual to a 'normal' reference sequence. On average, WES of an individual identifies 2,000-4,000 non-synonymous variants with minor allele frequency <1%. This limitation can be overcome by restricting sequence variant filtering to smaller regions of interest that are generated for instance by homozygosity mapping or linkage analysis 70 , or by analysing only shared variants across several affected individuals within the same family. These approaches enable DNA variants to be excluded from further consideration and allow an a priori restriction for the pool of potentially causal mutations. Finally, WES can result in the identification of incidental findings, which are not related to the indication for performing WES but might still be of medical importance to the patient. A policy statement with recommendations regarding the utility and reporting of incidental findings have been published by the American College of Medical Genetics 71 . Use of WES might also detect disease-causing genes that were not suspected on the basis of the patient's clinical presentation. For instance, by combining homozygosity mapping with WES in 10 sibling pairs with renal cystic ciliopathies, we detected the causative gene in seven of the 10 families studied 3 . In five families we identified mutations of known renal cystic ciliopathies genes; however, in two families we found mutations in other known CKDcausing genes, specifically SLC4A1 (a causative gene for distal renal tubular acidosis) and AGXT (the causative gene for hyperoxaluria type 1). Neither diagnosis had been made clinically and represented phenocopies for renal cystic cili opathies 3 . Other examples of phenocopies that have been identified through WES have been described for other non-renal conditions 72, 73 .
Identification of pathogenic pathways
The identification of disease-causing mutations using WES can provide new insights into disease patho genesis, as exemplified by WES analysis of patients with nephrotic syndrome. This condition is defined by proteinuria, with hypoalbuminaemia, oedema and hyper lipidaemia, and is categorized by the patient's clinical response to steroid therapy as either steroid-sensitive or steroid-resistant. SRNS is the second most frequent cause of CKD in children and young adults (TABLE 1) . The mechanisms of SRNS are poorly understood and no curative treatment is available. The most frequent renal histological feature of SRNS is FSGS, which carries a 33% risk of recurrence in kidney transplant recipients, thereby leading to ESRD 49 . Insights into the primary aetiology and pathomechanisms of SRNS through the identification of genes that, if mutated, cause recessive or dominant monogenic forms of SRNS, have provided fundamental insights into the disease mechanisms [14] [15] [16] 74 . The discovery of novel SRNS genes has led to the understanding that the renal glomerular podocyte represents the cell type at which these disease mechanisms converge 18 . Over 39 genes are now known to cause SRNS if mutated (TABLE 4) . Those genes encode proteins that can currently be grouped into the following four major categories: proteins that are associated with the glomerular slit membrane, such as nephrin (encoded by NPHS1) 14 , podocin (NPHS2) 74 , and CD2-associated protein (CD2AP) 75 ; proteins that are involved in actin binding and regulation and hence affect the podocyte cytoskeleton, such as those encoded by ACTN4 (REF. (FIG. 1) .
Consequences for therapy
A diagnosis of CKD in a patient aged <25 years should trigger the clinician to consider referring the patient for genetic analysis. Molecular analysis of early CKD-causing genes using panels of known genes is increasingly available. Following identification of a CKD-causing mutation, the patient should be referred to a clinical laboratory with Clinical Laboratory Improvement Amendments certification as well as for genetic counselling. Optimally, care for patients with monogenic CKD should be provided by a multidisciplinary team comprising nephrologists, urologists, and clinical geneticists.
Identification of the causative mutation might have therapeutic consequences for patients with SRNS that harbour mutations in genes involved in CoQ 10 biosynthesis, as these patients can receive CoQ 10 supplementation 53, 54 . CoQ 10 deficiency might lead to nephrotic syndrome through the excess production and accumulation of reactive oxygen species 81 . The finding that CoQ 10 treatment is beneficial for patients with SRNS resulting from mutations in CoQ 10 biosynthetic genes has opened a window of opportunity for these patients, especially since CoQ 10 is an innocuous food supplement that has a high safety profile. Initial case reports 82, 83 showed that CoQ 10 supplementation in patients with CoQ 10 deficiency secondary to mutations in its biosynthesis genes improved neurologic symptoms but failed to show any benefit on renal function, as advanced chronic renal failure had developed before the initiation of CoQ 10 supplementation. A subsequent case report 52 , however, suggested that early initiation of the treatment, immediately after the onset of renal symptoms, was beneficial in reducing proteinuria in a patient with nephrotic syndrome caused by recessive mutations in COQ2. This form of monogenic SRNS, for which further study is needed, provides one of The identification of monogenic causes of disease will improve the future categorization of diseases for the investigation of outcomes in clinical trials. In the immediate term, however, the identification of a disease-causing mutation already has several clinical implications, including the ability to provide the patient and their family with a definitive description of the cause of their disease; the potential to place the clinical phenotype into context by gene-specific stratification and through the delivery of personalized medicine; the ability to provide precise genetic counselling for family planning; to diagnose previously unrecognized affected family members; to avoid unnecessary diagnostic procedures, tests and treatments; to detect and treat asymptomatic (or subtle) extrarenal manifestations early; to provide guidance for the monitoring of potential future complications; and to guide advanced medical management on a gene-specific basis
.
In our opinion, mutation analysis by WES and indication-driven analysis of relevant gene panels can currently be recommended for all individuals who manifest with one of the following before 25 years-of-age: CKD, SRNS, increased echogenicity or two or more cysts on renal ultrasonography, urinary stone disease, CAKUT, or chronic glomerulonephritis. The likelihood of identifying a causative monogenic mutation is estimated to be ~20% in this setting and this rate will rise in the future as more disease genes and causative mutations are identified. Our understanding of the clinical consequences of monogenic mutations will rapidly accumulate as genotype-phenotype correlations are discovered and investigated over the coming years.
Conclusions and future directions Two-thirds of early-onset CKD is caused by CAKUT, SRNS, renal cystic ciliopathies or chronic glomerulonephritis. Over the past 10 years, >200 genes that if mutated can cause monogenic forms of these dis orders have been identified. High throughput exon sequencing using exon panels or WES now enables identification of the causative mutation in a high proportion (~20%) of individuals with early-onset CKD. Molecular genetic diagnostics can be planned in a well-defined, clinical indication-driven manner for patients with SRNS, cystic kidney diseases, CAKUT, glomerulonephritis, or nephrolithiasis or nephrocalcinosis. Indication-driven gene panel analysis with the use of next-generation sequencing is an emerging tool, which will continue to be used in clinical research and practice 72, 73 . The identification of novel disease-causing genes will enable molecular genetic diagnosis, aetiologic classification of disease for therapeutic trials and develop ment of animal models of disease, as well as small mol ecule screening for therapeutic purposes. Furthermore, the progress in high-throughput sequencing will ensure that additional CKD-causing genes will be detected in the near future. Findings from such studies could lead to more relevant aetiologic categorization of disease entities than can be provided by ultrasound imaging or histo pathology alone. Lastly, detection of monogenic causes of CKD already has implications for genetic counselling as well as for clinical management of patients with CKD. Might enable diagnosis of affected family members.
• Index patients with CAKUT caused by PAX2 or GATA3 mutations, for example, might have a parent, child or sibling with undiagnosed CAKUT, which is only detected by recognizing the genetic nature of the disease; this finding should trigger renal ultrasonographic screening for CAKUT in other family members • Genetic screening may enable the identification of asymptomatic individuals harbouring heterozygous COL4A4
or COL4A5 mutations, who should be monitored yearly for proteinuria and hypertension
Enable unnecessary diagnostic procedures, tests and treatments to be avoided • For example, renal biopsy is not needed in patients with congenital or infantile nephrotic syndrome secondary to NPHS1 or NPHS2 mutations or in patients with a characteristic nephronophthisis phenotype and NPHP1 mutations • For example, aggressive pretransplantation 'anti-recurrence' treatment should be avoided in kidney transplant recipients with focal segmental glomerulosclerosis secondary to NPHS2 mutations, which has a low risk of recurrence • For example, patients with CAKUT secondary to HNF1B mutations might have elevated liver function tests; acknowledging this finding as part of the HNF1B-spectrum can prevent unnecessary invasive investigation of liver abnormalities Guide advanced medical management on a gene-specific basis.
• For example, recessive mutations in CTNS establish a diagnosis of cystinosis and should trigger treatment with cystine-depleting agents • CoQ 10 supplements should be considered for patients with nephrotic syndrome who harbour mutations in genes of the CoQ 10 biosynthesis pathway • The finding of MYH9 mutations in patients with nephrotic syndrome should guide thrombocytopaenia management * Lumacaftor and ivacaftor are effective in patients who have a homozygous Phe508del mutation in CFTR 200 .
